Home | Careers | BI | Contact us

Sativex® receives regulatory approval in Israel

June 13, 2012

Neopharm Group and GW Pharmaceuticals plc announced that Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray) has received regulatory approval from the Israeli Ministry of Health for the treatment of spasticity and neuropathic pain due…

Neopharm Group Celebrates 70 years of Leadership and Innovation

January 2, 2012

Since it’s founding in 1941, Neopharm has made a meaningful difference to patient health through marketing and distribution of great medicines in Israel, and in 2012, the company will celebrate its 70th anniversary, an achievement…

Welcome to the New Neopharm Group website

January 1, 2012

Welcome to the New Neopharm Group website. As you’ve probably noticed things are looking quite different around here. Our new corporate website offers much more than just a facelift – on this new website, you…

What Neopharm Group Offers to Partners

December 26, 2011

Neopharm Group is positioned as the partner-of-choice and one-stop-shop for the multinational pharmaceutical industry. Major scientific and…

Home | About Us | Companies | Partnering | Research | Corporate Citizenship | Careers | Newsroom | Contact | Legal Notice

All Rights reserved, Neopharm Group, Israel | Design by: VAZA | Developed by: The Shark Lady